MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.035
AS - Asia 2.507
EU - Europa 2.452
SA - Sud America 323
AF - Africa 85
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.434
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.987
RU - Federazione Russa 1.149
CN - Cina 766
SG - Singapore 706
IT - Italia 503
HK - Hong Kong 355
KR - Corea 287
BR - Brasile 265
IE - Irlanda 186
VN - Vietnam 114
SE - Svezia 107
DE - Germania 96
PL - Polonia 91
IN - India 90
FI - Finlandia 76
NL - Olanda 68
FR - Francia 50
ID - Indonesia 44
JO - Giordania 40
GB - Regno Unito 37
AU - Australia 30
MA - Marocco 28
CA - Canada 26
AR - Argentina 24
ES - Italia 21
CH - Svizzera 18
MX - Messico 18
TR - Turchia 18
IR - Iran 17
ZA - Sudafrica 16
EC - Ecuador 14
CI - Costa d'Avorio 13
EG - Egitto 12
BD - Bangladesh 11
JP - Giappone 11
UA - Ucraina 11
AT - Austria 9
IQ - Iraq 9
BJ - Benin 7
PK - Pakistan 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
CO - Colombia 4
KE - Kenya 4
MY - Malesia 4
PH - Filippine 4
PY - Paraguay 4
UY - Uruguay 4
CL - Cile 3
GR - Grecia 3
LT - Lituania 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
NO - Norvegia 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
IM - Isola di Man 1
IS - Islanda 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
SI - Slovenia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.434
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.082
Singapore 533
Ashburn 352
Hong Kong 316
Hefei 309
Seoul 287
Dublin 186
Beijing 129
San Jose 127
Chandler 112
Fairfield 99
Milan 92
Florence 84
Warsaw 83
Kent 82
Los Angeles 67
Buffalo 52
Munich 51
Moscow 50
Altamura 45
Lawrence 45
Ho Chi Minh City 40
Mumbai 39
Boston 37
Seattle 35
Rome 34
Wilmington 33
Cambridge 32
Dallas 32
Jakarta 32
Woodbridge 32
Princeton 31
The Dalles 31
São Paulo 30
Lappeenranta 29
Paris 29
Turku 28
Hanoi 27
Melbourne 27
Casablanca 25
Houston 25
New York 23
Shanghai 22
Helsinki 19
Bengaluru 18
Clifton 18
Frankfurt am Main 17
Chicago 16
Abidjan 13
Rio de Janeiro 13
West Jordan 13
Johannesburg 12
Bern 11
Hamburg 11
Barcelona 10
Chennai 10
Dearborn 10
Istanbul 9
Medford 9
Modena 9
Tokyo 9
Belo Horizonte 8
Bologna 8
Brooklyn 8
Cairo 8
London 8
Naples 8
Pune 8
Quito 8
San Diego 8
Amsterdam 7
Ann Arbor 7
Catania 7
Cotonou 7
Denver 7
Manchester 7
Norwalk 7
Ottawa 7
Porto Alegre 7
Stockholm 7
Tehran 7
Toronto 7
Trieste 7
Turin 7
Atlanta 6
Burgum 6
Genoa 6
Guangzhou 6
Nuoro 6
Orem 6
Romola 6
Ankara 5
Council Bluffs 5
Gdansk 5
Livorno 5
Tianjin 5
Amman 4
Campinas 4
Da Nang 4
Dong Ket 4
Totale 5.336
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 322
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 195
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 190
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 184
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 183
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 170
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 170
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 162
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 162
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 161
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 161
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 158
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 157
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 157
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 151
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 149
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 148
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 144
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 143
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 141
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 139
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 139
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 136
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 135
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 135
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 134
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 131
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 131
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 129
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 128
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 125
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 123
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 122
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 121
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 120
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 119
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 117
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 115
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 110
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 110
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 109
Antibody-mediated cell depletion therapies in multiple sclerosis 109
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 105
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 105
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 103
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 102
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review 100
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 100
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 100
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 99
Magnetic Resonance intracranial Vessel Wall Imaging (VWI) in Susac Syndrome: potential relevance for diagnosis and therapeutic management. 98
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 96
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 96
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 96
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis 94
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 94
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) 92
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 91
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 88
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 85
Low positive predictive value of Multiple Sclerosis diagnostic criteria in demyelinating syndromes with red flags of better explanation. 81
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 78
Preface 78
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 77
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study 71
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT 70
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation 67
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 56
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 48
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 32
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK 11
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party 10
Totale 8.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.857
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.857
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202171 0 0 0 0 0 0 13 14 14 16 6 8
2021/2022205 2 15 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/20253.545 126 327 201 503 828 561 109 230 145 96 167 252
2025/20263.106 547 666 609 523 429 144 188 0 0 0 0 0
Totale 8.568